When he was announcing the PBS listing of one of these at-risk MS medicines late last year, having presumably been told that any price reduction would put it at risk, officials were probably well and truly in the process of manoeuvring the provider of another off-patent medicine brand into accepting an almost 50 per cent cut.
In a perfect world, the minister would not be in this position, and he might question the timeline
July 8, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Illumina taps medtech leader to head Australia and New Zealand operations
July 8, 2026 - - Latest News -
PYC Therapeutics names Thomas Ulmer as new chief financial officer
July 8, 2026 - - Australian Biotech -
In a perfect world, the minister would not be in this position, and he might question the timeline
July 8, 2026 - - Latest News -
Aegros completes Australia’s second large scale plasma fractionation plant
July 8, 2026 - - Latest News -
'But I've said it's really important that these two drugs stay on the PBS'
July 7, 2026 - - Latest News -
Just another attempt to create a new excuse to avoid a meaningful discussion about change
July 7, 2026 - - Latest News -
Australia must keep development manufacturing and jobs here to secure health and economic benefits
July 7, 2026 - - Latest News

